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Abstract
Effective regulation of transgene product in anatomically circumscribed brain tissue is dependent on the pharmacokinetics
of the regulating agent, the kinetics of transcriptional activation and degradation of the transgene product. We evaluated
rapamycin-regulated AAV2-GDNF expression in the rat brain (striatum). Regulated (a dual-component system: AAV2-
FBZhGDNF + AAV2-TF1Nc) and constitutive (CMV-driven) expression vectors were compared. Constitutively active AAV2-
GDNF directed stable GDNF expression in a dose-dependent manner and it increased for the first month, thereafter
reaching a plateau that was maintained over a further 3 months. For the AAV2-regGDNF, rapamycin was administered in a
3-days on/4-days off cycle. Intraperitoneal, oral, and direct brain delivery (CED) of rapamycin were evaluated. Two cycles of
rapamycin at an intraperitoneal dose of 10 mg/kg gave the highest GDNF level (2.7560.01 ng/mg protein). Six cycles at
3 mg/kg resulted in lower GDNF values (1.3660.3 ng/mg protein). Interestingly, CED of rapamycin into the brain at a very
low dose (50 ng) induced GDNF levels comparable to a 6-week intraperitoneal rapamycin cycle. This study demonstrates
the effectiveness of rapamycin regulation in the CNS. However, the kinetics of the transgene in brain tissue, the regulator
dosing amount and schedule are critical parameters that influence the kinetics of accumulation and zenith of the encoded
transgene product.
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Introduction
One promising disease-modifying strategy for Parkinson’s
Disease (PD) is the provision of neurotrophic factors for protection
and restoration of the damaged dopaminergic (DA) innervation of
the basal ganglia [1,2,3,4,5,6,7,8]. The most clinically advanced
family of factors is defined by the prototype, glial cell line-derived
neurotrophic factor (GDNF). Based upon strong preclinical data of
its protective effects on DA neurons, several clinical trials were
undertaken in which recombinant GDNF was infused either into
cerebral ventricles [9,10] or into the putamen [11,12] through an
indwelling catheter. The significance of these clinical studies
remains controversial [12,13,14,15,16], although apparent efficacy
was reported in one trial [11,12]. One issue identified in these
studies was whether the infused GDNF was adequately localized to
the target region. The fact that some trial participants developed
anti-GDNF antibodies [11,12] and that a few treated non-human
primates (NHP) showed cerebellar pathology [17], suggests that
GDNF protein delivery was sub-optimal. Nevertheless, parenchy-
mal GDNF infusion has the significant advantage that treatment
can be terminated if necessary, a feature unavailable to clinical
gene transfer at present. GDNF gene therapy, however, is
attractive because it provides an effectively localized expression
of GDNF at levels many orders of magnitude lower than protein
infusions with impressive efficacy in Parkinsonian nonhuman
primates (NHP) in both neuroprotective [18] and neurorestorative
[8,19] paradigms. The possibility, therefore, of developing a
regulated gene therapy vector is highly attractive since it promises
to combine localized GDNF delivery with the capacity to adjust
steady state levels through exogenous administration of a brain-
penetrant small molecule regulator.
Regulated gene expression can be achieved via a chimeric gene
construction linking a regulatory cis element upstream of the gene
to be transcribed. One such strategy is to use a drug that can cross
the blood-brain barrier to act on drug-dependent promoters that
directly activate or repress target gene transcription. The
rapamycin-regulated transcriptional control system uses rapamy-
cin (or analogs) to dimerize the activation (p65) and DNA-binding
(ZFHD1) domains of a chimeric transcription factor through the
rapamycin-binding domains of the proteins FRAP and FKBP.
The activated transcription factor then binds to zinc finger motifs
upstream of a minimal promoter (from human interleukin-2) and
drives expression of the encoded transgene [20]. In the case of
GDNF, regulated expression is kinetically complex because the
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no simple relationship between activation of transcription, protein
biogenesis, secretion and subsequent extracellular accumulation of
GDNF in the transduced brain region (striatum).
As part of an effort to effectively translate a regulated gene
transfer platform into clinical studies we undertook the studies
reported below. These experiments address the kinetics of GDNF
biogenesis and accumulation with various rapamycin dosing
regimens with a rapamycin-regulated AAV2-GDNF vector system
(AAV2-regGDNF) delivered into the rat striatum. It should be
noted that this study examined only the kinetics of this system and
not its therapeutic implications. We found that 2 cycles of 3 days
on/4 days off rapamycin at an intraperitoneal dose of 10 mg/kg,
yielded a high GDNF level (2.7560.01 ng/mg protein). In turn,
six cycles of lower dose, 3 mg/kg rapamycin [22], resulted in
lower GDNF levels (1.3660.3 ng/mg protein). Further studies in
Parkinsonian NHP should reveal whether such dosing is well
tolerated and able to promote dopaminergic regeneration.
Materials and Methods
Construction and preparation of the constitutive AAV2-
GDNF
This vector was previously described in studies by Johnston
et al. [23]. Three different concentrations were chosen for the
time-course study: 1.1610
13 vg/ml; 6.05610
12 vg/ml; and
1.1610
12 vg/ml. The control vector, AAV2-LacZ, was described
previously [24]
Construction and preparation of the rapamycin-
regulated AAV2-GDNF
The constitutively expressed repressor/transactivator plasmid,
pFBGR(TF1Nc.3), was constructed by excising the
CMV.TF1Nc.3 expression cassette from pAAV.CMV.TF1Nc.3
(Avigen, Alameda, CA) with NotI. This cassette was inserted into
NotI-digested pFBGR [25]. The rapamycin-regulated plasmid
pFBZ(hGDNF) was constructed by first creating a shuttle plasmid
harboring the Z12I promoter, termed pBSZ12I. The Z12I
promoter was removed from pAV.Z12I.AADC (Avigen, Alameda,
CA) using NotI and ClaI and then exchanged with the CMV
promoter of the shuttle plasmid pBSFBRmcs [26] to create
pBSZ12I. Creation of pBSZ12I(hGDNF) was done by removal of
the hGDNF coding sequence from pAV.Z12I.hGDNF (Avigen,
Alameda, CA) with ClaI and ligation into ClaI-digested pBSZ12I.
The final pFBZ(hGDNF) plasmid was generated by excision of the
expression cassette from pBSZ12I(hGDNF) with NotI and
insertion into NotI-digested pFBGR.
Recombinant AAV (2 L total culture volume per vector) was
generated via a baculovirus-based method described previously
[25]. Cultures were processed through 3 freeze/thaw cycles
consisting of an overnight freeze at –80uC and a 2-h thaw at 37uC
prior to purification and concentration. After cell lysis, cultures
were centrifuged at 1290 x g for 10 min to remove cellular debris.
Crude supernatants were subsequently treated with Benzonase (20
units/ml; Sigma-Aldrich, St. Louis, USA) and incubated at 37uC
for 1 h. Treated crude supernatants were filtered through 0.2-mm
polyethersulfone membranes prior to purification.
Viruses were purified on a Biologic DuoFlow FPLC (BioRad,
Hercules, CA) with an attached XK50/20 column containing
70 ml of AVB Sepharose chromatography media (GE Healthcare,
Piscataway, NJ), as previously described [27] with the following
modifications. Flow rates were established at 2.7 ml/min. Elution
fractions were collected in sterile tubes containing 0.5 ml of
sterilized Tris, pH 8.0, to neutralize citrate acidity. Peak virus-
containing fractions, determined by OD280 measurement, were
pooled and concentrated to 2 ml with VivaSpin 20 ultraconcen-
tration cassettes (MWCO 100,000; Sartorius-Stedim, Bohemia,
NY). Concentrated virus was dialyzed for 2 h in 2 L of sterilized 1x
PBS with 2 mM MgCl2, dispensed and frozen at 280uC. Viral
titers were determined by quantitative real-time PCR [8] with
primer/probe sets specific for the Z12I or CMV promoter
sequence. Rapamycin-induced expression of hGDNF was con-
firmed by transduction of HEK293A cells (Invitrogen, Carlsbad,
CA) and ELISA-based measurement of hGDNF protein concen-
trations (Promega, Madison, WI). The titers of both vectors were
5.5610
12 vg/ml. They were mixed 1:1 before infusion into rat
brain.
Animals
Experiments were performed with male Sprague-Dawley rats
(Charles River Laboratories; Wilmington, MA) each weighing
350–400 g. All procedures were approved by, and in accordance
with, the regulations of the Institutional Animal Care and Use
Committee of the University of California, San Francisco
(approval number: AN082508), and all efforts were made to
minimize suffering.
Stereotactic surgery
We infused both vector systems, constitutive AAV2-GDNF and
rapamycin-regulated (AAV2-FBZhGDNF and AAV2-TF1Nc at a
1:1 ratio) into the rat striatum bilaterally (total volume 15 ml for
30 min; the infusion rate was 0.5 ml/min) by convection-enhanced
delivery (CED) as previously described [21]. For the time-course
study with the constitutive AAV2-GDNF, 84 rats divided into two
groups were used. Rats from Group I (n=42) were infused with
the maximum dose of the vector, 1.65610
11 vg, into their right
hemispheres, while the left hemispheres were injected with 1/2 log
of the maximum dose, 9.07610
10 vg. In turn, rats from Group II
(n=42) were injected with 10-fold less than the maximum dose,
1.65610
10 vg into the left hemisphere and 1.65610
11 vg of the
control vector AAV2-LacZ into the right hemisphere. At each
time point (3 days, 7 days, 14 days, 21 days, 1 month, 2 months, 3
months, and 4 months post-transduction) 5 rats from each group
were euthanized and their brains were rapidly removed and the
striatum was dissected bilaterally and immediately frozen for
further processing (Fig. 1). To visualize the extent of GDNF
expression, 2 rats from Group I and 2 rats from Group II were
maintained alive for 4 months at which time their brains were
processed for immunostaining for GDNF as described previously
[21].
For the time-course study with rapamycin-regulated AAV2-
GDNF (AAV2-regGDNF), 22 rats were infused (CED) bilaterally
with 15 ml of a 1:1 mixture of two vectors: AAV2-FB-hGDNF
(2.12610
12 vg/ml) and AAV2-FB-ZTFINc3 (2.12610
12 vg/ml).
Thirty days after transduction, rats received daily doses of either
rapamycin (10 mg/kg) or vehicle (control) for 3 consecutive days.
Animals were euthanized at 1, 4, 8, 14, 21, and 28 days after
rapamycin administration. Six striata from 3 rats at each time
point were extracted and processed for GDNF ELISA. Three
control rats were given rapamycin excipient and euthanized on
day 1. Similarly to the Group I for the constitutive AAV2-GDNF,
brains of 2 rats euthanized 4 days after rapamycin treatment were
processed for the immunohistochemical evaluation of GDNF
expression [21].
For the testing of different dosing regimens of rapamycin, 33
rats were used (7 groups for intraperitoneal (i.p.) injections; 2
groups for oral administration; 1 group for direct brain infusion
(CED); and 1 control group for vector infusion only without
Rapamycin-Regulated AAV2-GDNF in the Rat Brain
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each animal provided 2 striata and the data, therefore, are the
mean 6 SEM of 6 determinations. In addition, 2 rats were tested
for endogenous (baseline) levels of GDNF in the striatum (see
schematic in Table 1).
Administration of rapamycin
Rapamycin (LC Laboratories, Woburn, MA) was administered
intraperitoneally at different doses and regimens to induce the
highest achievable levels of GDNF expression (Table 1).
Rapamycin was first dissolved in N,N-Dimethyl-acetamide
(DMAC) and then subsequently diluted for i.p. injection in vehicle
consisting of 10% DMAC, 40% polyethylene glycol 400, 40%
water, and 10% Tween 80. In addition, two groups of rats (Groups
I and J) received Rapamune (Sirolimus) from WyethH
Philadelphia, PA by oral gavage (0.5 mg/kg). For direct infusion
into the brain (Group K), rapamycin was first dissolved in the
above vehicle at a concentration of 4 mg/ml and subsequently
serially diluted (1:100 followed by 1:16) in PBS to a final
rapamycin concentration of 2.5 mg/ml. Twenty microliters (total
50 ng) were infused (CED) into each hemisphere. Conditions for
that infusion were identical to CED for the vector delivery. Two
daily doses of 50 ng were infused and rats were euthanized 4 days
thereafter.
Individual tissue punch collections
In addition to the above experiments, we created two separate
groups of rats in which GDNF level was measured in small
(1.5 mm) punches rather than entire striatum. The purpose of this
experiment was to demonstrate whether there was any difference
between GDNF ELISA performed on the entire striatum results vs
restricted tissue punches. Four rats were infused bilaterally (8
hemispheres for analysis) with AAV2-regGDNF (conditions as
above). Rats were euthanized after 3 (n=2) and 6 (n=2) cycles of
rapamycin 3 mg/kg. Punches were taken as described below.
GDNF enzyme-linked immunosorbent assay (ELISA)
Rats were euthanized and their brains were immediately
collected. After dissection, whole striata were stored at –80uC.
For the experiment in which individual tissue punches were
collected, the freshly removed brains were first snap-frozen in cold
(-80uC) isopentane by full immersion. Frozen brains were
subsequently cut into 1-mm coronal slices in the rat brain blocker
(David Kopf Instruments, Tujunga, CA). Six individual punches
were taken from 3 consecutive striatal slices (2 per slice). All
punches were taken with an 1.5-mm Harris Uni-Core
TM, Electron
Microscopy Sciences; Hatfield, PA). All samples were later
homogenized with a tissue Tearor
TM, model 985370 (BioSpec
Products, Inc., Bartlesville, OK) in 250 ml of ice-cold buffer
containing 100 mM potassium phosphate (pH 7.8), 0.2% Triton
X-100 and protease inhibitors (Complete MiniH; Roche, Palo
Alto, CA) and homogenates were centrifuged at 13,000 x g for
15 minutes. The supernatant solutions were collected and GDNF
concentrations measured by ELISA with a commercially available
kit (Promega, Madison, WI) as described previously [23].
Immunohistochemistry
After euthanasia, rats were transcardially perfused with cold
PBS and then 4% paraformaldehyde (PA) in PBS. The brains were
Figure 1. Study design for time-course of GDNF expression in the rat brain after transduction with the constitutive AAV2-GDNF.
doi:10.1371/journal.pone.0027728.g001
Table 1. Summary of in vivo GDNF induction from the AAV2-
regGDNF after various dosing regimens.
Rapamycin regime
Striatal GDNF
ng/mg protein
Endogenous GDNF 0
Intraperitoneal administration
A. Vector only 0.0560.01
B.16(3610 mg/kg) 0.5460.25
C.26(3610 mg/kg) 2.75±0.01
D.16(361 mg/kg) 0.160.01
E.36(361 mg/kg) 0.1360.02
F.16(363 mg/kg) 0.1660.06
G.36(363 mg/kg) 0.8060.42
H. 6 6(363 mg/kg) 1.36±0.3
Oral administration
I.1 60.5 mg/kg 0.0560.01
J.36(360.5 mg/kg) 0.0960.05
Direct CED into the brain
K. 2650 ng 1.26±0.32
doi:10.1371/journal.pone.0027728.t001
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briefly in PBS, transferred to a 30% w/v sucrose solution in
0.01 M PBS for cryopreservation and then cut into 40-mm serial
coronal sections on a cryostat. Frozen sections were collected in a
series in antifreeze solution and stored at 280uC. Selected sections
were immunostained for GDNF. After 3 washes in PBS, the
sections were blocked in 1% v/v H2O2 for 20 min. After another
extensive wash in PBS, sections were incubated in blocking
solution (2% v/v normal horse serum and 0.01% v/v Tween-20 in
PBS) for 30 min, followed by incubation in primary antibody
solution (goat polyclonal anti-GDNF antibody from R&D Systems
Inc, Minneapolis, MN; 1:300 in blocking solution) overnight at
room temperature. After three washes in PBS with 0.01% Tween-
20, sections were allowed to react for 1 h with biotinylated horse
anti-goat IgG (concentration 1:300; Vector Laboratories, Burlin-
game, CA), followed by a 1-h incubation in Streptavidin-HRP
(1:300; Vector Laboratories) and a further brief wash in PBS.
Immunoreactivity was visualized by DAB/H2O2 reaction. Sec-
tions were mounted onto slides, dried and covered with glass
coverslips.
Results
Kinetics of GDNF accumulation in the rat brain after
transduction with the constitutive AAV2-GDNF vector
Initially, GDNF accumulation was analyzed in rat striatum
transduced with AAV2-GDNF in which GDNF expression is
driven by the constitutive human CMV promoter. Vector was
infused into normal rat striata [21,28] at one of 3 doses
(16.5610
10,9 . 1 610
10 and 1.65610
10 vg). Animals from each
group were euthanized at various times and GDNF content
measured (Fig. 1). In all three groups, striatal GDNF increased
for the first month and thereafter was maintained at a fixed level
for up to 4 months in all three groups. At the maximum vector
dose, mean GDNF content by ELISA was , 11 ng/mg tissue
protein. The medium and low doses of vector directed
correspondingly lower GDNF tissue concentrations, 6–7 and 2–
3 ng/mg tissue protein, respectively (Fig. 2). The threshold level
of GDNF detectable by the GDNF ELISA kit was , 0.025 ng/
mg protein. Immunohistochemical (IHC) evaluation of GDNF
expression from the last time-point confirmed robust, widespread,
and vector dose-dependent signal within the injected hemisphere
(Fig. 3a-c).
Kinetics of GDNF induction from the AAV2-regGDNF
induced by rapamycin dosing
To evaluate the inducible vector system, two vectors, AAV2-
FBZhGDNF and AAV2-TF1Nc, were co-infused into rat
striatum (see Methods) at a 1:1 ratio. Thirty days after
transduction, rats received daily intraperitoneal doses of either
rapamycin (10 mg/kg) or vehicle (control) for 3 consecutive days.
Animals were euthanized and striata processed for GDNF
content (ELISA) at several time points after rapamycin admin-
istration. In the absence of rapamycin, no GDNF could be
detected. In contrast, tissues from rapamycin treated animals
expressed 3.561.4 ng GDNF/mg tissue protein 4 days after the
last administration of inducer. GDNF expression detected by
IHC revealed only focal expression in the vicinity of the cannula
track (Fig. 3d). The time-course of GDNF expression suggests
that the effect of rapamycin on GDNF expression is persistent,
extending out to more than 14 days after the last rapamycin
injection. GDNF levels gradually declined from the peak at 4
days to baseline 3-4 weeks later (Fig. 4).
Effect of rapamycin dosing regimen on striatal GDNF
concentration
The time-course of GDNF accumulation after rapamycin
administration helped in the design of a general schedule (cycle:
3-days on/4-days off) of rapamycin administration (Fig. 5) to test
a range of rapamycin dosing regimens. Thirty days after vector
infusion, rats were randomized into 11 groups of 3 rats. Seven
groups received i.p. rapamycin. Two groups received oral
rapamycin (RapamuneH) at 0.5 mg/kg, the maximum dose of
rapamycin deliverable orally. One group received a direct
parenchymal infusion of rapamycin by convection-enhanced
delivery (CED) in two daily doses of 50 ng. Control animals
(Group A) received i.p. excipient. The results are summarized in
Table 1.
Individual tissue punch collections
The ELISA results from individual punch collections are
tabulated in Table S1 (supplementary data). The mean values
are lower than the values generated from the entire striata
(Table 1).
Discussion
We evaluated the ability of the dimerizer-regulated gene
expression to achieve controlled production of GDNF after striatal
administration of AAV2-regGDNF in the rat brain. Our
experiments addressed the kinetics of GDNF biogenesis, and
accumulated levels with various rapamycin dosing regimens.
All animals that received i.p. rapamycin showed statistically
significant increases in striatal GDNF levels (Groups B – H). Oral
dosing was less effective (Groups I & J), although 3 cycles of oral
drug treatment did produce a significant increase in GDNF
Figure 2. Time-course of GDNF expression in the rat brain after
transduction with the constitutive AAV2-GDNF. Three doses of
the vector were used and striatal levels of GDNF were measured in the
tissue homogenates by GDNF ELISA at various time points after
transduction. In all three groups, striatal GDNF increased for the first
month and was maintained thereafter at a fixed level for 3 more
months. The level of expressed GDNF was proportional to the dose of
the vector used.
doi:10.1371/journal.pone.0027728.g002
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upon repeat dosing was also evident in i.p. dosing. For example, 2
dosing cycles of rapamycin at 10 mg/kg produced a 5-fold
increase in GDNF content (Groups B & C). This schedule of
rapamycin dosing produced the greatest tissue concentration of
GDNF. However, 10 mg/kg is not a tolerable clinical dose;
intravenous doses of rapamycin analogs have only reached 3–
5 mg/kg in cancer patients [22,29,30]. We therefore investigated
chronic dosing with more clinically compatible regimens. Three
cycles of 1 or 3 mg/kg (Groups E & G) gave GDNF levels lower
than with two cycles of 10 mg/kg. However, 3 mg/kg provided
GDNF levels of 0.80 ng/mg protein comparable to levels reported
to be neuroprotective against MPTP in marmosets [31], although
this study was not designed to evaluate this parameter. This level
was further enhanced by 6 cycles of 363 mg/kg to 1.460.3 ng
GDNF/mg protein, approximately 50% of the level obtained after
two cycles of 10 mg/kg of rapamycin. These data suggest that high
steady-state levels of GDNF in brain tissue can be achieved by
chronic rapamycin dosing. Interestingly, direct brain infusion
(CED) of rapamycin at a very low dose (50 ng) resulted in GDNF
levels of 1.360.3 ng GDNF/mg protein, comparable to a 6-week
363 mg/kg i.p. rapamycin schedule. This result suggested that
rapamycin does not readily cross the blood-brain barrier (BBB).
The fact that only a low dose of rapamycin is needed for such
induction if delivered directly to the brain suggests perhaps a new
strategy for the use of rapamycin-regulated vectors within the CNS
in which the vectors are infused into target tissue with an
indwelling catheter that delivers very low doses of rapamycin. In
addition, new analogues of rapamycin (Deforolimus, AP21967,
Ariad Inc.) with higher potency and/or better pharmacokinetic
properties could further improve gene regulation and eliminate
systemic toxicity. We conclude that a clinically compatible dosing
schedule with rapamycin is achievable but it is not clear whether
the levels of GDNF obtained are sufficient to promote neuro-
regeneration in Parkinsonian primates.
The long-term consequences of high doses of GDNF in PD
patients will not be evident until late clinical data become
available. Regulation of transgene expression by an FDA-
approved drug should provide an additional safety margin and
may enable fine tuning of GDNF action at the individual patient
level by adjusting the schedule of administered inducer. In our
study, repeated induction of GDNF expression from the AAV2-
regGDNF clearly resulted in a progressive accumulation of GDNF
protein. The experiments were performed with a 3-days on/4-days
off regime (cycles) based on the time-course of GDNF expression
from AAV2-regGDNF after rapamycin induction. Striatal con-
centrations of GDNF peaked at day 4 and returned to the
threshold of detection 21 days later. This result was very similar to
the findings of Auricchio et al [32] who used a similar rapamycin-
regulated AAV2 system with erythropoietin (Epo) where peak
levels were observed at day 3 with return to basal levels by day 21.
The highest dose of rapamycin we used (10 mg/kg i.p.) is not
acceptable clinically. However, a dose of 3 mg/kg, lower than that
used clinically [22], resulted in accumulation of GDNF of 1.4 ng/
mg protein (Group H), suggesting that repeat dosing is clinically
feasible. It should be noted that 2 ng GDNF/mg protein expressed
from the constitutive AAV2-GDNF was the lowest GDNF level
that elicited recovery in MPTP-lesioned monkeys [19]. We have
not established, however, whether lower steady-state levels of
GDNF can also promote recovery in lesioned primates. The
present data, nevertheless, demonstrate that the rapamycin-
inducible GDNF expression system is fully functional in rats and
is able to produce presumptively bioactive levels of GDNF.
It should be noted that whole striata were taken for our analyses
(ELISA) to avoid sampling errors from individual punch
collections. We define such results as ‘‘gross striatal values’’.
Concerns may be raised regarding the use of entire striata taken
for ELISA since, potentially, the readouts might have underesti-
mated the levels of exogenously expressed GDNF (due to
averaging and lowering the values of GDNF within the entire
striatal tissue). Our data from individual punch collections (Table
S1) indicated more wide-ranging values (higher standard devia-
tions) with the lower mean than for the data generated from the
entire striata (Table 1). This confirmed and validated the usage of
whole striata for ELISA rather than single tissue snips. ‘‘Gross
striata values’’ assure that the entire injected structure is taken into
consideration with more precise (total) quantification of GDNF
expression.
Figure 3. Immunostaining for GDNF expressed in rat striatum
from constitutive AAV2-GDNF (a-c) and rapamycin-regulated
AAV2-GDNF (d). The constitutive vector was infused at 3 different
doses: 16.5610
10 vg (a), 9.07610
10 vg (b), and 1.65610
10 vg (c). The rats
were euthanized 4 months after transduction. Robust, widespread
signal (proportional to vector dose) confirmed continuous GDNF
expression within the injected hemisphere. Much of the signal
represents GDNF secreted into the striatal parenchyma. The dose of
AAV2-regGDNF was 4.12610
10 vg and rats were euthanized 4 days after
3-day Rapamycin regimen (3610 mg/kg). In contrast to the constitutive
vector, the AAV2-regGDNF revealed only focal expression of GDNF
localized mainly around the cannula track (d). Since this vector induces
GDNF secretion only in the presence of rapamycin, the GDNF signal was
limited and did not extend beyond the injected striatum (no GDNF
accrual upon a single rapamycin cycle).
doi:10.1371/journal.pone.0027728.g003
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AAV2-regGDNF, higher titers could be used. Our dual compo-
nent vector system produced lower levels of GDNF than the
constitutive vector partly because of the difference in titers. AAV2-
regGDNF was infused at a dose of 4.12610
10 vg (1:1 mixture of
both vectors at 5.51610
12 vg/ml), 4-fold less than the highest dose
of the constitutive vector (16.5610
10 vg). Immunohistochemical
staining of GDNF also confirmed a much wider distribution and
robust signal from the constitutive AAV2-GDNF, whereas AAV2-
regGDNF showed only focal GDNF expression in the vicinity of
the cannula track (Fig. 3). It is important to keep in mind that this
rather restricted signal was the result of just one induction cycle
(3610 mg rapamycin/kg) with no GDNF accrual over time (slow
tissue clearance [21]). The rats transduced with the constitutive
AAV2-GDNF were euthanized after 4 months of continuous
production and secretion of GDNF within the rat striatum.
Relative strength of promoters is also likely responsible for
differences. One of the disadvantages of the two-vector system is
also the need to co-transduce neurons with both vectors for
regulation to occur. The method of co-transduction with two
separate AAV vectors compensates for the restrictions concerning
gene insertion into the small AAV vectors. The AAV co-
transfection may raise concerns regarding efficiency of transgene
expression from two mixed AAV vectors and injected into a single
site. Fan et al. showed that the tyrosine hydroxylase (TH) gene and
also the aromatic L-amino acid decarboxylase (AADC) gene were
simultaneously transduced into rat striatal cells via two separate
AAV vectors, AAV-TH and AAV-AADC [33]. Immunostaining
showed that TH and AADC were co-expressed efficiently in the
same striatal cells in vitro and in vivo (.95% double-positive cells
were counted). Moreover, co-transduction with these two vectors
resulted in more effective dopamine production and more
remarkable behavioral recovery in 6-hydroxydopamine (6-
OHDA)-lesioned rats, compared with rats receiving AAV-TH
alone (p,0.01). Later, the same group tried a triple transduction
with AAV’s expressing TH, AADC, and GTP Cyclohydrolase I
(GCH) [34]. Similarly to their previous results, triple transduction
resulted in greater dopamine production in denervated striatum of
parkinsonian rats (exceeding double transduction with AAV-TH
and AAV-AADC). Molecular studies by Yang et. al [35] have
demonstrated that intermolecular recombination between mono-
mer circular intermediates (AAV2-GFP and AAV-Alkphos) is, at
least in part, responsible for the formation of AAV circular
concatamers associated with long-term episomal persistence and
transgene expression. New single-vector systems that can accom-
modate both the regulatory components and the transgene,
eliminating the need for co-transduction have already been
designed [36,37,38]. It should also be emphasized that, for clinical
applications, precise targeting and distribution of the vector is
warranted. Real-time convective delivery (RCD) of gene therapy
vectors has been proposed to address this need [39,40]. A similar
dual-component AAV2-regAADC vector system has also been
Figure 4. Time-course of GDNF induction from the AAV2-regGDNF induced by rapamycin dosing. Thirty days after transduction, rats
received daily intraperitoneal doses of either rapamycin (10 mg/kg) or vehicle (control) for 3 consecutive days. Animals were euthanized and striata
processed for GDNF measurements (ELISA) at various days after rapamycin administration. The time-course of GDNF expression suggests that the
effect of rapamycin induction on GDNF expression extends out to more than 14 days after the last rapamycin injection, peaking at day 4.
doi:10.1371/journal.pone.0027728.g004
Figure 5. General schedule of rapamycin administration. Thirty
days after vector infusion, rats were randomized into 11 groups of 3
rats. Seven groups received intraperitoneal (i.p.) rapamycin; two groups
received oral rapamycin and one group received a direct infusion (CED)
of rapamycin into the brain. Control animals (n=3) received i.p.
excipient. The detailed rapamycin dosing regimens are listed in Table 1.
doi:10.1371/journal.pone.0027728.g005
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Decarboxylase (AADC) expression has been shown in the striatum
of unilaterally 6-OHDA-lesioned rats by i.p. injection of
rapamycin. Induction of AADC in the lesioned striatum was
associated with the development of L-dopa-induced turning
behavior. This effect was completely reversible and repeatable.
In another long-term (6-year) study of regulated erythropoietin
(Epo) expression in NHP skeletal muscle transduced by AAV1-
based vectors, Rivera et al showed that circulating levels of
recombinant Epo are undetectable in the absence of rapamycin or
its analogs but could be reliably induced (26 times) to levels that
significantly increased hematocrit [37]. Taken together these
studies establish that the rapamycin system can be tightly regulated
with an appropriate dosing schedule.
If GDNF gene therapy is to become a truly practical mode of
treatment of PD, the therapeutic gene will need to be expressed at
controlled levels. As we have shown, these levels will depend on
the dose of the administered vector and, in case of regulated
vectors, the precise dosing regimes of the inducing agents. To our
knowledge, we are the first to have made the novel observation
that simple changes to rapamycin dosing regimens have dramatic
effects on GDNF expression. No research team has yet been able
to advance a regulated gene therapy vector into clinical study.
Clinical validation of the rapamycin-regulated expression system
would be a major innovation in gene therapy, and would likely
trigger renewed interest in applications of this approach. As these
are only the first steps in controlling expression of transgenes, it is
also important to understand the limitations of regulated gene
therapy systems before advancing to clinical trials. More studies in
animal models should address issues of safety. The ideal solution
would be to develop a system that would place a transgene under
the control of both a tissue-specific promoter and a disease-specific
promoter. The first reports of such advanced systems have already
been published [42] and may soon be used in human studies.
Supporting Information
Table S1 In vivo GDNF induction from AAV2-regGDNF
after 3- and 6-week of Rapamycin dosing (3 mg/kg) –
results from individual striatal punches. Six individual
punches (1.5 mm) were taken from each striatum. The details are
described in Materials and Methods.
(PDF)
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